Next Article in Journal
Techno-Economic Analysis on an Industrial-Scale Production System of Polyhydroxyalkanoates (PHA) from Cheese By-Products by Halophiles
Previous Article in Journal
Modes of Occurrence of Chromium and Their Thermal Stability in Low-Rank Coal Pyrolysis
 
 
Review
Peer-Review Record

A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9

Processes 2022, 10(1), 16; https://doi.org/10.3390/pr10010016
by Md. Al Saber 1,†, Partha Biswas 2,3,†, Dipta Dey 4, Md. Abu Kaium 2, Md. Aminul Islam 2, Miss Ismoth Ara Tripty 5, MD. Hasanur Rahman 3,6, Tanjim Ishraq Rahaman 3,6, Md. Yeaman Biswas 2, Priyanka Paul 4, Md. Ataur Rahman 7,8,9, Md. Nazmul Hasan 10,* and Bonglee Kim 8,9,*
Reviewer 1: Anonymous
Reviewer 2:
Processes 2022, 10(1), 16; https://doi.org/10.3390/pr10010016
Submission received: 15 November 2021 / Revised: 9 December 2021 / Accepted: 15 December 2021 / Published: 23 December 2021
(This article belongs to the Section Biological Processes and Systems)

Round 1

Reviewer 1 Report

The work of Al Saber et al. entitled A Comprehensive Review of Recent Advancements of Cancer Immunotherapy and Generation of CAR T-Cell by CRISPR-Cas9 discusses the possibility of using immunotherapy in the treatment of neoplastic diseases in an interesting way. 

In the introduction, the Authors define the concept of immunotherapy, describe the involvement of the immune system in the recognition and elimination of cancer cells, and emphasize that the CRISPR-Cas9 technique can be used as genetic alteration and multiple genomes editing tool that can enhance the efficacy of CAR-T cell in which it can effectively recognize the solid tumor antigens. 

A detailed description of the activation of T cell by antigenic response illustrated with aesthetic figures and a table containing examples of antigens and their endo domains being the target for CAR-T cell therapy prove the high  substantive quality of the work.

Significance of T cell in cancer treatment is emphasized in the next chapters. The authors explain the causes of T cell failure for recognizing the cancer antigens and provide examples of neoplastic diseases in which immunotherapy has already been used. 

It is extremely valuable to present the basics of oncological therapies using different lymphocyte subpopulations. The detailed explanation of the role of immunomodulators and antibodies, the definition of cancer vaccines and the description of oncology therapy using nanoparticles also deserve recognition. 

In their work, Al Saber et al. focused on the explanation of the strategy of T cell modification through using the CRISPR-Cas9 genome editing tool. The entire modification of T cell receptor process has been described clearly, in detail and illustrated in understandable figures. This chapter collects an extremely wide range of literature reports and may become a valuable resource. 

I sincerely congratulate the Authors on such multithreaded work and recommend the work for quick publication. 

Author Response

>>Response: We are grateful to reviewer 1 for his wonderful comments regarding our Review Article.

Reviewer 2 Report

2021.12.04

I have read with interest article" A Comprehensive Review of Recent Advancements of Cancer Immunotherapy and Generation of CAR T-Cell by CRISPR-Cas9” Although the topic itself is of interest; however, there are major concerns still need to be addressed by the authors before considering for publication.

 

Minor points

  1. The title should be corrected- CRISPR-Cas9 – need to be deleted. Or seem over enhanced part. In addition, estimated molecular weights for all detected proteins should be also indicated in all western blotting

 

  1. Generally, the 110 resistant properties of T cells stimulate the induction of CAR-T cell which 111 can inhibit the proliferation of solid tumors. - Should be added reference.

 

  1. After this part 5. The current immunotherapies which are used in cancer treatment - A better presentative table should be provided.

 

  1. Figure 3. Cancer cells are removed from patients>> removed are misused.

 

  1. 6. Nanoparticle-based cancer immunotherapy >> sentences should be replaced into                discussion part,

 

  1.  Table 3 >> unnecessary
  2.   The strategy of T cell modification through using the CRISPR-Cas9 genome editing  tool- If the author claims the effect of CRISPR-Cas9 as a Cancer Immunotherapy, author should show molecular structure or genetic modification in CRISPR-Cas9.

.

Comments for author File: Comments.pdf

Author Response

Comment 01) The title should be corrected- CRISPR-Cas9 – need to be deleted. Or seem over enhanced part. In addition, estimated molecular weights for all detected proteins should be also indicated in all western blotting.

>>Response: Here, We are focusing on generation of CAR-T Cell by CRISPR-Cas9 and our Introduction and Conclusion part included the significance of CRISPR-Cas9 generated CAR-T Cell. So we think, It is important to include the CRISPR-Cas9 in our title.    

We have reviewed this topic based on the published articles. Unfortunately, we didn’t find molecular weights for all detected proteins.  

Comment 02) Generally the 110 resistant properties of T cells stimulate the induction of CAR-T cell which 111 can inhibit the proliferation of solid tumors. - Should be added reference.

>>Response: We have added the reference in our revised manuscript in the page 03, line (110-112).    

Comment 03) After this part 5. The current immunotherapies which are used in cancer treatment - A better presentative table should be provided.

>>Response: We have added a new table entitled as Table 03: The Tabular Representation of the Current Immunotherapy Techniques Which are Used for Cancer Treatment worldwide.

 Comment 04) Figure 3. Cancer cells are removed from patients>> removed are misused.

>>Response: We have corrected the error in our updated manuscript.

Comment 05) Nanoparticle-based cancer immunotherapy >> sentences should be replaced into discussion part,

>>Response: In our review article, there have no discussion section. But we included it in Introduction part. 

Comment 06) Table 3 >> Unnecessary

>>Response: We have removed the table in our updated manuscript.

Comment 07) The strategy of T cell modification through using the CRISPR-Cas9 genome editing  tool- If the author claims the effect of CRISPR-Cas9 as a Cancer Immunotherapy, author should show molecular structure or genetic modification in CRISPR-Cas9.

>>Response: As our primary object to show the possibility of Crispr/cas9 in generation of CAR-T cells against cancer we described the way to deliver gene through Crispr system and also showed the available recent findings and success on that system. We have also discussed the targeted gene to modify in the T cell to successfully target cancer cells. There are several plasmid constructs has been discussed here. So, if we include all the construct molecular it will be a huge topic.

Back to TopTop